Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF. Nash, R. A., Johnston, L., Parker, P. M., Slattery, J. T., Storer, B., Furlong, T., Anasetti, C., Appelbaum, F. R., Lloid, C. M., Blume, K., Deeg, H. J., Forman, S. J., Kiem, H. P., Martin, P. J., Schubert, M., Witherspoon, R. P., Storb, R. AMER SOC HEMATOLOGY. 2003: 240A
View details for Web of Science ID 000186536700844